ISASS Policy Statement – Cervical Total Disc Arthroplasty
- Public Policy
- ISASS Policy Statement – Cervical Total Disc Arthroplasty
- Liz Vogt
- September 25, 2012
ISASS Policy Statement – Cervical Total Disc Arthroplasty
Symptomatic cervical disc disease (CDD) refractory to non‐surgical care is currently treated with anterior cervical discectomy and fusion (ACDF) with good clinical results reported1‐3. Fusion does however eliminate natural motion increasing stresses on adjacent levels, and progressive degeneration at the levels around the fusion has been reported. The rate of symptomatic adjacent segment degeneration (ASD) is estimated to occur at 3% per year and to be present in up to 25% of patients at 10 years4. The etiology for ASD is likely a combination of the altered biomechanical environment imposed by fusion and the patients’ underlying disc disease or genetic predisposition4,5. ASD after a prior cervical fusion is not a benign condition and has been reported to lead to an annual incidence of additional surgery ranging from 0.7% to 3.8%1,2,6‐8 . In response, motion‐sparing alternatives such as cervical total disc arthroplasty (TDA) have been developed to mitigate the biomechanical contribution to ASD.
Biomechanical studies have demonstrated that TDA in the cervical spine preserves motion at the treated level and facilitates more physiologic distribution of forces at adjacent levels compared with fusion. In an in vivo study, Sasso and colleagues demonstrated that the levels adjacent to a fusion exhibited significantly greater sagittal plane translation compared with that seen after TDA9. In a cadaveric spine model, Dmitriev et al found that TDA maintains physiologic motion and adjacent level intradiscal pressures, while fusions produced elevated adjacent level pressures and altered kinemetics10. Similarly, other studies of TDA have demonstrated relative protection of the adjacent levels with maintenance of more physiologic motion.11‐12.
Recent data from the multi‐center, prospective, randomized United States Investigational Device Exemption trials comparing ACDF with TDA support TDA as either equivalent or superior to ACDF, with an acceptably low rate of complications. At 2 years post‐operatively, Heller et al recently demonstrated that TDA had significantly greater improvement in Neck Disability Index (NDI) and neck pain with greater overall success compared with ACDF, with a similar rate of implant‐related adverse events, and a quicker return to work13. Murrey et al recently reported excellent clinical outcomes with a significantly lower rate of secondary surgeries with TDA at 2 years (1.9%) compared with ACDF (8.5%), and lower narcotic usage14. Mummaneni et al reported similar findings at 2 years with TDA achieving a significantly greater improvement in NDI, neurologic success, and physical component SF‐36 scores, while requiring significantly fewer secondary surgeries and re‐operation for ASD15. At 2 years post‐operatively, it was also reported that TDA patients maintained or improved their range of motion13‐16. Although not a controlled study, Robertson et al nonetheless demonstrated that patients who received TDA required significantly fewer medical treatments for symptomatic ASD at 2 years compared with fusion (33.0% ACDF vs 1.3% TDA) 17. The evidence clearly supports clinical efficacy, and in some instances superiority of TDA over ACDF, with multiple studies reporting less symptomatic ASD and significantly lower re‐operation rates at the 2 year time point.
Device‐specific complications of TDA that may occur include heterotopic ossification, device subsidence, vertebral body fracture, and implant extrusion, all of which have been reported to occur at acceptably low rates13‐16. Though short term results indicate clinical benefit of TDA over ACDF, the spine community collectively awaits longer term results to assess device performance and specifically, the fate of the index level, adjacent levels, and facet joints11,18.
Given the Level I data from multiple studies with over 1000 TDA and 963 ACDF patients enrolled and various implant types with 2 year follow‐up, the International Society for the Advancement of Spine Surgery (SAS) concludes that cervical disc arthroplasty is non‐experimental, as described for FDA approved devices. TDA is a viable treatment option in patients who meet the patient indications as prescribed in the FDA approvals and is at least equivalent and often superior to ACDF. Even at the relatively early 2 year post‐operative time point, several high quality studies have shown significantly lower re‐operation rates after TDA when compared to ACDF. Further data will be needed to characterize and expand upon the apparent benefits of TDA. SAS will keep abreast of the reported literature on longer term results with TDA in general, as well as reports from studies with new disc replacement devices.
1. Bohlman H, Emery S, Goodfellow D, Jones P. Robinson anterior cervical discectomy and arthrodesis for cervical radiculopathy: long‐term follow‐up of one hundred and twenty‐ two patients. J Bone Joint Surg Am. 1993; 75:1298‐1307.
2. Yue W, Brodner W, Highland T. Long‐term results after anterior cervical discectomy and fusion with allograft and plating: a 5‐ to 11‐year radiologic and clinical follow‐up study. Spine 2005; 30: 2138‐44.
3. Kaiser M, Haid R, Subach B, Barnes B, Rodts G. Anterior cervical plating enhances arthrodesis after discectomy and fusion with cortical allograft. Neurosurgery. 2002; 50: 229‐38.
4. Hilibrand AS, Carlson GD, Palumbo MA, et al. Radiculopathy and myelopathy atsegments adjacent to the site of a previous anterior cervical arthrodesis. J Bone Joint Surg Am. 1999 Apr; 81(4): 519‐28.
5. Ishihara H, Kanamori M, Kawaguchi Y, et al. Adjacent segment disease after anterior cervical interbody fusion. Spine J. 2004 Nov‐Dec; 4(6): 624‐8.
6. Lunsford L, Bissonette D, Jannetta P, Sheptak P, Zorub D. Anterior surgery for cervical disc disease, part 1: treatment of lateral cervical disc herniation in 253 cases. J Neurosurg 1980; 53:1 – 11
7. Teramoto T, Ohmori K, Takatsu T, et al. Long‐term results of the anterior cervical spondylosis. Neurosurgery 1994; 35:64 – 8.
8. Williams J, Allen M, Harkess J. Late results of cervical discectomy and interbody fusion: some factors influencing the results. J Bone Joint Surg 1968;50A:277‐86
9. Sasso RC, Best NM. Cervical kinematics after fusion and bryan disc arthroplasty. J Spinal Disord Tech. 2008 Feb; 21(1): 19‐22.
10. Dmitriev AE, Cunningham BW, Hu N, et al. Adjacent level intradiscal pressure and segmental kinematics following a cervical total disc arthroplasty: an in vitro human cadaveric model. Spine. 2005 May 15; 30(10): 1165‐72.
11. Chang UK, Kim DH, Lee MC, et al. Changes in adjacent‐level disc pressure and facet joint force after cervical arthroplasty compared with cervical discectomy and fusion. J Neurosurg Spine. 2007 Jul; 7(1): 33‐9.
12. Chang UK, Kim DH, Lee MC, et al. Range of motion change after cervical arthroplasty with ProDisc‐C and prestige artificial discs compared with anterior cervical discectomy and fusion. J Neurosurg Spine. 2007 Jul; 7(1): 40‐6.
13. Heller JG, Sasso RC, Papadopoulos SM, et al. Comparison of BRYAN cervical disc arthroplasty with anterior cervical decompression and fusion: clinical and radiographic results of a randomized, controlled, clinical trial. Spine. 2009 Jan 15; 34(2): 101‐7.
14. Murrey D, Janssen M, Delamarter R, et al. Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc‐C total disc replacement versus anterior discectomy and fusion for the treatment of 1‐level symptomatic cervical disc disease. Spine J. 2009 Apr; 9(4): 275‐ 86.
15. Mummaneni PV, Burkus JK, Haid RW, et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. JNeurosurg Spine. 2007 Mar; 6(3): 198‐209.
16. Sasso RC, Best NM, Metcalf NH, et al. Motion analysis of bryan cervical disc arthroplasty versus anterior discectomy and fusion: results from a prospective, randomized, multicenter, clinical trial. J Spinal Disord Tech. 2008 Aug; 21(6): 393‐9.
17. Robertson JT, Papadopoulos SM, Traynelis VC. Assessment of adjacent‐segment disease in patients treated with cervical fusion or arthroplasty: a prospective 2‐year study. J Neurosurg Spine. 2005 Dec; 3(6): 417‐23.
18. Ordway NR, Lu YM, Zhang X, et al. Correlation of cervical endplate strength with CT measured subchondral bone density. Eur Spine J. 2007 Dec; 16(12): 2104‐9.